Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PETER H WIN

Allopathic & Osteopathic Physicians Ophthalmology

NPI
1124040209
CMS profile
141025
Location
ARCADIA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$408.04

22 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $408.04 22

By paying entity

PY2022 · entire year · sorted by reported total

Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PETER H WIN

NPI 1124040209 · CMS profile ID 141025

Allopathic & Osteopathic Physicians / Ophthalmology

ARCADIA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1124040209?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PETER H WIN, NPI 1124040209, CMS profile ID 141025. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124040209?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). PETER H WIN, NPI 1124040209, CMS profile ID 141025. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124040209?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
PETER H WIN, NPI 1124040209, CMS profile ID 141025, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1124040209?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

22 matching records · $408.04 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 22 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–22 of 22.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Sun Pharmaceutical Industries Inc. $24.1212/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947876383 CMS
Apellis Pharmaceuticals, Inc. $22.2712/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 964259507 CMS
Regeneron Healthcare Solutions, Inc. $33.6211/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927476499 CMS
Sun Pharmaceutical Industries Inc. $23.6610/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947876377 CMS
Regeneron Healthcare Solutions, Inc. $32.9508/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927476493 CMS
Sun Pharmaceutical Industries Inc. $5.3408/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947876371 CMS
Mallinckrodt Hospital Products Inc. $18.9308/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937532737 CMS
Sun Pharmaceutical Industries Inc. $25.0408/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947876365 CMS
Sun Pharmaceutical Industries Inc. $19.1006/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947876359 CMS
Bausch & Lomb Americas Inc. $20.2306/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957525959 CMS
Mallinckrodt Hospital Products Inc. $20.7405/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937532735 CMS
Genentech USA, Inc. $21.7505/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950776891 CMS
Spark Therapeutics, Inc. $21.4505/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938541617 CMS
Novartis Pharmaceuticals Corporation $21.7505/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894453769 CMS
EYEVANCE PHARMACEUTICALS LLC $14.4804/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896704993 CMS
Genentech USA, Inc. $21.8204/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950788843 CMS
Sun Pharmaceutical Industries Inc. $5.4404/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947876353 CMS
Alimera Sciences, Inc. $11.2703/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896603017 CMS
Sun Pharmaceutical Industries Inc. $5.1403/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947876347 CMS
Sun Pharmaceutical Industries Inc. $15.0002/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947876341 CMS
Alcon Vision LLC $18.6702/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 905115645 CMS
Sun Pharmaceutical Industries Inc. $5.2701/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947876335 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $376.26 27
PY2020 $369.48 18
PY2021 $467.02 31
PY2022 $408.04 22
PY2023 $529.17 23
PY2024 $307.75 14
PY2025 $396.97 16

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $11,800.65 3
PY2025 Principal investigator $1,018,714.70 358
PY2024 Recipient $41,692.12 4
PY2024 Principal investigator $792,747.79 884
PY2023 Recipient $95,996.85 6
PY2023 Principal investigator $408,946.29 24
PY2022 Recipient $123,777.97 8
PY2022 Principal investigator $843,108.89 22
PY2021 Principal investigator $927,697.26 16
PY2020 Principal investigator $132,922.86 4
PY2019 Principal investigator $29,997.25 6

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

30 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,710.24 12/22/2023 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 977209645
Principal investigator 1 Roche TCRC, Inc. $2,500.00 12/15/2023 Non-covered Recipient Entity
Win Retina
Oral Treatment of NPDR No dispute reported 06/30/2026 1040645197
Principal investigator 1 Genentech, Inc. $33,090.00 12/12/2023 Non-covered Recipient Entity
PETER HO WIN MD INC
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1040422057
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,026.14 11/22/2023 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 977198733
Principal investigator 1 Roche TCRC, Inc. $7,001.00 10/31/2023 Non-covered Recipient Entity
Win Retina
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1040645169
Principal investigator 1 Roche TCRC, Inc. $29,848.00 10/31/2023 Non-covered Recipient Entity
Win Retina
Phase 2 study of Anti IL6 MAb with RBZ in combination in patients with DME No dispute reported 06/30/2026 1040645185
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20,372.75 10/02/2023 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 977183799
Recipient Genentech, Inc. $12,194.00 08/22/2023 Covered Recipient Physician Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1040138279
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,359.38 07/25/2023 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 977169557
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,240.00 07/07/2023 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 977162727
Recipient Genentech, Inc. $19,133.00 07/05/2023 Covered Recipient Physician Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1040138267
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,260.05 07/03/2023 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 977159821
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17,161.52 05/24/2023 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 977111083
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,861.00 05/17/2023 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 977109731
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,524.50 05/17/2023 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 977109735
Principal investigator 1 Roche TCRC, Inc. $11,214.00 05/02/2023 Non-covered Recipient Entity
Win Retina
Phase 2 study of Anti IL6 MAb with RBZ in combination in patients with DME No dispute reported 06/30/2026 1040645129
Principal investigator 1 Roche TCRC, Inc. $5,766.00 05/02/2023 Non-covered Recipient Entity
Win Retina
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1040645147
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,977.22 04/26/2023 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 977105735
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $70,896.54 03/20/2023 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 977100421
Recipient Genentech, Inc. $935.85 03/01/2023 Covered Recipient Physician Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1040138255
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,057.97 02/22/2023 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 977093343
Principal investigator 1 Roche TCRC, Inc. $53,930.00 02/20/2023 Non-covered Recipient Entity
Win Retina
Phase 2 study of Anti IL6 MAb with RBZ in combination in patients with DME No dispute reported 06/30/2026 1040645097
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31,590.00 02/16/2023 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 977092541
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $30,780.00 02/16/2023 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 977092545
Recipient Genentech, Inc. $50,090.00 02/07/2023 Covered Recipient Physician Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1040138223
Recipient Genentech, Inc. $12,113.00 02/07/2023 Covered Recipient Physician Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1040138235
Recipient Genentech, Inc. $1,531.00 02/07/2023 Covered Recipient Physician Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1040138243
Principal investigator 1 Roche TCRC, Inc. $18,872.00 02/03/2023 Non-covered Recipient Entity
Win Retina
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1040645113
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14,405.78 02/02/2023 Non-covered Recipient Entity
WIN RETINA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 977090533
Principal investigator 1 Roche TCRC, Inc. $9,502.20 01/24/2023 Non-covered Recipient Entity
Win Retina
Oral Treatment of NPDR No dispute reported 06/30/2026 1040645213